Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...7475767778798081828384...123124»
  • ||||||||||  Review, Journal:  A concise review of the changing landscape of hepatocellular carcinoma. (Pubmed Central) -  Sep 26, 2021   
    Options for first-line systemic therapy of advanced HCC include sorafenib, lenvatinib, and atezolizumab plus bevacizumab...Options for subsequent therapy following disease progression include regorafenib, cabozantinib, ramucirumab, lenvatinib, nivolumab, nivolumab plus ipilimumab, sorafenib, or pembrolizumab...Improved tolerance of therapies for advanced HCC may lead to reduction in treatment discontinuation and contribute to better patient outcomes. Managed care pharmacists should understand the recent efficacy and safety data, guideline recommendations, and treatment algorithms for management of HCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Clinical, Review, Journal:  Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. (Pubmed Central) -  Sep 26, 2021   
    Similarly, in the post-sorafenib setting, a number of recent positive clinical trials have been reported, and they indicate that regorafenib, cabozantinib, and ramucirumab are effective and safe in the second-line setting...In the present review, we introduce the current data for second-line systemic treatment and beyond in hcc. A treatment algorithm is also suggested, based on the best available evidence and expert opinion.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Charge-Assisted Bond and Molecular Self-Assembly Drive the Gelation of Lenvatinib Mesylate. (Pubmed Central) -  Sep 24, 2021   
    In conclusion, the charge-assisted bond N-H in LM molecule and intermolecular non-covalent interactions drived the hydrogel formation of LM in aqueous media. This study elucidates the gelation mechanism and gel properties of LM hydrogel, which would be helpful to figure out strategy to eliminate its gelation fundamentally and pave the way for its further formulation development in future.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) -  Sep 24, 2021   
    P2,  N=54, Enrolling by invitation, 
    This study elucidates the gelation mechanism and gel properties of LM hydrogel, which would be helpful to figure out strategy to eliminate its gelation fundamentally and pave the way for its further formulation development in future. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed:  Post-Marketing Surveillance of Lenvima in Korean Patients (clinicaltrials.gov) -  Sep 23, 2021   
    P=N/A,  N=3000, Active, not recruiting, 
    Assessing treatment intensity, safety and efficacy, low-dose lenvatinib treatment was well tolerated by RRDTC patients and displayed acceptable drug efficacy and outcomes. Recruiting --> Active, not recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open:  Pembrolizumab And Lenvatinib In Leptomeningeal Metastases (clinicaltrials.gov) -  Sep 23, 2021   
    P2,  N=19, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Journal:  Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma. (Pubmed Central) -  Sep 22, 2021   
    In our small cohort of heavily pretreated patients with ACC, the combination of LEN/PEM was associated with objective responses in a subset of patients without significant toxicity. This combination should be formally investigated in phase II clinical trial with robust correlative studies to identify predictors for response.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Last-line therapy success with the combination of lenvatinib and pembrolizumab in metastatic melanoma (Stream 4) -  Sep 20, 2021 - Abstract #ADO2021ADO_394;    
    Subsequently, progressive filia appeared again, which is why cytostatic therapy with dacarbazine was carried out...The disease control rate of 65% shown is also quite good for this patient group. The combination therapy with lenvatinib and pembrolizumab has been well tolerated by the patient since 02/21 and after only 2 months of therapy there were clearly regressive metastases and in some cases CR in all organ systems.
  • ||||||||||  lenvatinib / Generic mfg.
    Journal:  Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma. (Pubmed Central) -  Sep 19, 2021   
    The 3 patients with PR are on therapy with Lenva and Pembro for> 4 months, 2 of them with a reduced dose of Lenva (14 mg and 10 mg) due to NW. Considering these results, we propose that the target trough concentration of lenvatinib could be 36.8-71.4 ng/mL for maintaining disease control status and reducing grade ≥ 3 toxicity in the treatment of HCC.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Review, Journal, PD(L)-1 Biomarker, IO biomarker:  New approaches to first-line treatment of advanced renal cell carcinoma. (Pubmed Central) -  Sep 18, 2021   
    Additional systemic first-line treatments for clear cell RCC include axitinib plus pembrolizumab, pazopanib, and sunitinib for favorable-risk patients and ipilimumab plus nivolumab, axitinib plus pembrolizumab, axitinib plus avelumab, and cabozantinib for intermediate- or poor-risk patients. In this review of novel approaches for first-line treatment of advanced RCC, we present an overview of current treatment strategies, the basis behind emerging treatment approaches, a summary of key results from the pivotal studies using tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy, novel treatments and strategies under development, and efforts for identifying biomarkers to guide treatment decisions.
  • ||||||||||  Avastin (bevacizumab) / Roche, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen, Nexavar (sorafenib) / Bayer, Amgen
    Review, Journal, PD(L)-1 Biomarker:  Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. (Pubmed Central) -  Sep 16, 2021   
    While only lenvatinib proved to be non-inferior against sorafenib in a phase III (REFLECT trial), regorafenib (RESORCE trial), ramucirumab (REACH-2), and cabozantinib (CELESTIAL) have been approved second-line therapy in phase III clinical trials...Likewise, adjuvant therapy and prompt management of the recurrences holds the key to prolong OS and DFS. This review discusses the management options of HCC patients with PVTT.